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Adeno-associated virus serotype 2 (AAV-2) has been developed as a gene therapy vector.
Antibody and cell-mediated immune responses to AAV-2 or AAV-2-transfected cells may
confound the therapeutic use of such vectors in clinical practice. In one of the most detailed
examinations of AAV-2 immunity in humans to date, cell-mediated and humoral immune responses
to AAV-2 were characterized from a panel of healthy blood donors. The extent of AAV-2-specific
antibody in humans was determined by examination of circulating AAV-2-specific total IgG levels
in plasma from 45 normal donors. Forty-one donors were seropositive and responses were
dominated by IgG1 and IgG2 subclasses. Conversely, AAV-2-specific IgG3 levels were
consistently low in all donors. Cell-mediated immune recall responses were detectable in nearly
half the population studied. In vitro restimulation with AAV-2 of peripheral blood mononuclear cell
cultures from 16 donors elicited gamma interferon (IFN-c) (ten donors), interleukin-10 (IL-10)
(eight donors) and interleukin-13 (IL-13) (four donors) responses. Using a series of overlapping
peptides derived from the sequence of the VP1 viral capsid protein, a total of 59 candidate T-cell
epitopes were identified. Human leukocyte antigen characterization of donors revealed that the
population studied included diverse haplotypes, but that at least 17 epitopes were recognized by
multiple donors and could be regarded as immunodominant. These data indicate that robust
immunological memory to AAV-2 is established. The diversity of sequences recognized suggests
that attempts to modify the AAV-2 capsid, as a strategy to avoid confounding immunity, will not be
feasible.
INTRODUCTION
Adeno-associated virus serotype 2 (AAV-2) is a replication-
deficient parvovirus that infects humans, but produces no
significant pathology (Blacklow et al., 1968a). The virus
consists of a 5 kb single-stranded DNA genome, contained
within a non-enveloped icosahedral capsid (Xie et al.,
2002). The virus is replication-deficient and requires co-
infection with a helper virus such as adenovirus (Ad) or
herpes simplex virus (HSV) in order to disseminate
(Atchison, 1970; Atchison et al., 1965). Several serotypes
of AAV have been investigated for use as gene therapy
vectors or recombinant vaccine vehicles (Arruda et al.,
2005; High et al., 2004; Kaplitt et al., 2007; Moss et al.,
2004, 2007; Yue et al., 2008; Zhang et al., 2003). Although
AAV-2 has a relatively small transgene cloning capacity
(Kremer & Perricaudet, 1995), a number of features make
it an attractive gene therapy vector. The virus has an ability
to transduce dividing and non-dividing cells across a range
of tissue types (Clark et al., 1997; Flotte et al., 1993; Kaplitt
et al., 1994; Koeberl et al., 1997) and is capable of defined
integration on human chromosome 19, offering the
opportunity for stable, controlled transgene expression
(Kotin et al., 1990). Finally, AAV-2 is assumed to induce
minimal host immune responses, perhaps due to its helper
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virus dependence. The modest immune responses reported
to date have suggested a reduced risk of vector or
transduced cell destruction following administration
(Zaiss et al., 2002; Zaiss & Muruve, 2005).
The innate immune response to AAV-2 appears to be weak
and transient in animal models (Samulski & Giles, 2005;
Zaiss et al., 2002). However, little is known about the
immune response to AAV-2 infection in humans, beyond
the prevalence of infection (Blacklow et al., 1968a, b; Gao
et al., 2004). Observation of the adaptive response to AAV-
2 in animal models has demonstrated robust primary
responses, including specific neutralizing antibody
(Halbert et al., 1997; Xiao et al., 1999, 2000). The human
antibody response to AAV-2 has been characterized, but
seroprevalence varies between 30 and 96% depending on
the population sampled (Chirmule et al., 1999; Erles et al.,
1999; Halbert et al., 2006). This broad range might reflect
the lack of standardized methods for assessing AAV-2
serology. AAV-2 infection is thought to have occurred in at
least 20% of humans before the age of 10 years (Erles et al.,
1999). The detection of AAV DNA in amniotic fluid also
suggests that the virus may be present at birth in many
humans, possibly due to reactivated latent infection in the
mother during pregnancy (Tobiasch et al., 1994).
The cell-mediated adaptive immune response to AAV has
received little attention and there has been some assump-
tion that AAV does not provoke a significant response
(Bu¨ning et al., 2003; Hernandez et al., 1999; Samulski &
Giles, 2005; Zaiss & Muruve, 2005). The detection of AAV-
2-specific IgM (Erles et al., 1999) might indicate that AAV-
2 behaves like a T-cell-independent antigen. However,
there is evidence of notable cell-mediated responses to
AAV-2 from a recent gene therapy trial which reported
declining transgene expression and indications of tissue
damage, with concurrent cytotoxic T-cell responses
(Manno et al., 2006). Mouse models have since been used
to characterize T-cell responses to AAV-2 in greater detail
(Chen et al., 2006; Li et al., 2007; Wang et al., 2007).
However, inbred mouse strains display limited MHC
diversity in comparison with the highly polymorphic
human leukocyte antigen (HLA) genes, and cell-mediated
immunity in mice may not reflect immunity in human
populations.
Based on the emerging data on cell-mediated immunity in
humans and animal models, it is clear that the cell-
mediated response to AAV-2 needs further characterization
in the natural host if the virus is to be used confidently in a
clinical setting. Thus, to assess the feasibility of repeated
use of AAV-2 vectors in human populations, the immune
response to AAV-2 was characterized from a panel of 45
human blood donors. A high seroprevalence was observed
and this was further characterized by examination of the
immunoglobulin subclasses evoked by natural infection.
For the first time, to our knowledge, IgG responses were
correlated with proliferative cell-mediated responses from
the same donors. Furthermore, these were compared with
HLA haplotype and an analysis of the profile of cytokine
responses induced by AAV-2 stimulation. Finally, a large
number of T-cell epitopes were identified on the AAV-2
virus capsid. This study is, to our knowledge, the most
complete characterization of the human immune response
against AAV-2 to date, examining both arms of the
adaptive response. The diversity of stimulatory targets
identified on the AAV-2 capsid and the prevalence of the
cell-mediated immune response detected undermine the
notion that the AAV-2 capsid might easily be modified to
avoid cell-mediated immunity.
METHODS
Human peripheral blood mononuclear cell (PBMC) and blood
plasma donations. Human whole blood was provided by 45
anonymous Irish healthy donors. PBMCs were isolated by density-
gradient centrifugation (Lymphoprep; Axis-Shield) as described
previously (Ryan et al., 1998). Isolated PBMCs were resuspended in
8 % (v/v) heat-inactivated FCS/RPMI 1640 medium (cRPMI)
(Invitrogen). Blood plasma was isolated from whole blood by
centrifugation at 10 000 g for 10 min. Human material was acquired
and used in accordance with approval from the local Research Ethics
Committee [National University of Ireland (NUI) Maynooth].
Virus preparation. AAV-2 for immunological assays was provided
by the Regenerative Medicine Institute (REMEDI; NUI, Galway) and
consisted of an unmodified AAV-2 capsid encasing a modified AAV-2
genome encoding a reporter gene, as previously described (Stender
et al., 2007). Virus was purified using an iodixanol density gradient
followed by elution through a heparin column. Titres were
determined by real-time PCR following DNase1 and proteinase K
degradation. Concentrations were expressed as DNase-resistant
particles per ml (d.r.p. ml21). Virus preparations were resuspended
in sterile buffer (PBS, 1 mM MgCl2, 2.5 mM KCl) and stored at
280 uC. Reagents for vector preparation were sterilized prior to use.
Virus capsid peptides. The full VP1 sequence incorporates the VP2
and VP3 sequences of the AAV-2 capsid (Xie et al., 2002). A panel of
91 20-mer peptides were synthesized mostly with a 12-mer overlap to
adjacent sequences (Supplementary Table S1, available in JGV
Online). Peptides were synthesized commercially (Mimotopes) and
provided lyophilized. These were reconstituted in 0.1% (v/v) acetic
acid at a concentration of 25 mg ml21, split into aliquots and stored
at 280 uC. Before use, peptides were diluted in PBS to a working
concentration of 1 mg ml21.
AAV-2-specific total IgG ELISA. Total IgG levels were determined
in plasma from donors using an optimized in-house assay. Ninety-
six-well microassay plates (Nunc) were coated with AAV-2 at
16109 d.r.p. ml21 in carbonate coating buffer (150 mM Na2CO3,
350 mM NaHCO3, pH 9.6) for 12 h at 4 uC. Plates were blocked
using 5% (w/v) sucrose, 1% (w/v) BSA, 0.05% (v/v) Tween 20 in
PBS. Blood plasma was diluted in 1% (w/v) skimmed milk powder in
PBS and incubated at 37 uC for 2 h before detection of human IgG
using a biotinylated anti-human IgG (Sigma-Aldrich). Detection was
performed using a streptavidin–horseradish peroxidase conjugate and
tetramethyl benzidine substrate. Five washes were performed between
each step. In the absence of AAV-2-specific IgG international
standards, two donors (22 and 41), previously characterized as
reference donors, were selected as representative seronegative and
seropositive samples. These samples were included in all assays to
allow inter-assay comparison. AAV-2-specific IgG data for the
negative reference sample were assigned an AAV-2 antibody titre of
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1 unit, whilst the reference seropositive donor was assigned an AAV-2
antibody titre of 10 units. This allowed quality control and
normalization of results for meaningful comparison of data between
assays. Samples were considered seropositive if they scored above the
seronegative cut-off plus two standard deviations.
AAV-2-specific IgG subclass ELISA. IgG subclass concentrations
were determined in plasma samples from 41 AAV-2-IgG-seropositive
blood donors. Assays were performed in an adaptation of the protocol
for total IgG detection. Plates were probed for human IgG using anti-
human IgG subclass-biotin antibodies for subclasses IgG1–IgG4
(Merck). Detection and washing were performed as for the total IgG.
To validate these assays in the absence of international reference
standards, a series of verification assays were performed using the
above detection reagents to detect reference sera with standard
concentrations of purified human IgG 1, 2, 3 or 4 (Nordic
Laboratories) directly coated to the assay plate. In addition, the
detection reagents for IgG1–4 were validated against a similar but
unrelated virus (parvovirus B19) prevalent in this population.
Representative data for IgG3 are given in Supplementary Fig. S1
(available in JGV Online).
Proliferation assay. Proliferation in response to AAV-2 restimula-
tion was determined from PBMC cultures isolated from 41 healthy
Irish blood donors. Only viable, non-apoptotic PBMC populations
were used. Human PBMC (16106 cells ml21) were cultured in
triplicate with AAV-2 (161010 d.r.p. ml21) or VP1 peptide (40 mg
ml21), cRPMI alone (negative control) or with concanavalin A (Con
A) (5 mg ml21) (positive control). Cultures were incubated at 37 uC,
5% CO2 for 96 h. After 96 h, 100 ml supernatant was removed from
each well and frozen at 220 uC for cytokine analysis. Culture media
were then replaced with cRPMI containing 3H-thymidine (92.5 mBq
ml21) and incubated for 5 h, before detection of radioactive
incorporation by scintillation counting (Ryan et al., 2007). Results
(c.p.m.) were expressed as stimulation indices (SI), calculated as the
fold proliferation increase over the negative control (Corcoran et al.,
2000). For assays employing VP1 peptides, SI values were considered
positive if greater than one standard deviation above the mean SI for
stimulated wells.
Definition of T-cell epitopes. Each VP1 peptide sequence used
(Supplementary Table S1) possessed a 12-mer overlap with one
upstream and one downstream sequence (except for the terminal
peptides), so it was likely that any given epitope would be present in
two adjacent peptides. Only responses where two or more adjacent
peptides supported positive proliferation were considered to repres-
ent a valid epitope. In parallel, a bioinformatics approach was used to
predict HLA class I- and class II-restricted epitopes within the AAV-2
VP1 capsid sequence (SYFPEITHI epitope prediction algorithm)
(Rammensee et al., 1999). Predicted sequence output sizes were set at
9-mer for class I epitopes and 15-mer for class II epitopes. Due to the
large number of sequences generated for each HLA allele, only
epitopes with a score of .20 were used for comparison with
sequences detected in vitro.
Detection of cytokines. Cytokine levels were determined in
supernatants from 16 PBMC cultures representing samples that
supported proliferation in response to AAV-2 stimulation, and where
sample abundance allowed analysis. Commercial human gamma
interferon (IFN-c) and human interleukin (IL)-10 ELISA kits
(Immunotools) or matched antibodies for human IL-13 (R&D
Systems) were used for cytokine detection, according to the
manufacturer’s instructions, except for IL-13, where antibody was
diluted in carbonate coating buffer to 4 mg ml21. Cytokine concen-
trations were determined by comparison with reference standards of
known concentration.
Characterization of HLA haplotypes. HLA haplotypes were
characterized for 16 PBMC donors supporting in vitro proliferative
responses to AAV-2 stimulation described above. Sequence-specific
primer (SSP) PCR for HLA A, B, C, DR and DQ were performed.
DNA was isolated from PBMC using a Generation Capture Column
kit (Qiagen) according to the manufacturer’s protocol. HLA A, B, C,
DR and DQ were characterized using an SSP-based PCR kit (Texas
BioGene) in a split 96-well tray format. Amplified samples were
resolved on a 2% agarose gel and analysed using SSPal HLA analysis
software (Texas BioGene) following the manufacturer’s protocol.
RESULTS
AAV-2-specific IgG1 and IgG2 are prevalent in a
population of Irish blood donors
The reported seroprevalence of AAV-2-specific antibody is
highly variable (Chirmule et al., 1999; Erles et al., 1999;
Murphy et al., 2009). Therefore, the seroprevalence of
AAV-2-specific total IgG was examined in a population of
healthy Irish volunteer blood donors. Plasma from 45
donors was assayed for AAV-2-specific IgG by indirect
ELISA using in-house reference sera as controls. Donors
were considered AAV-2-seropositive if the IgG level was
two standard deviations greater than a known seronegative
sample. Forty-one of the 45 donors assayed displayed AAV-
2-specific IgG above this cut-off and were therefore
described as seropositive (Fig. 1a). Using this approach,
the mean titre of AAV-2-specific IgG observed in
seropositive donors was 9.4±5.2 units.
Whilst total IgG gives an indicator of virus exposure in a
population, it does little to inform understanding of the
immunological mechanisms in operation. Therefore,
plasma samples from IgG-seropositive donors were further
examined to determine the IgG subclasses involved in the
specific recognition of AAV-2 (Fig. 1b–e). Significant levels
of AAV-2 specific IgG1 were detected in all IgG-positive
samples assayed (P¡0.05), with a mean concentration of
11.9±6.7 mg ml21 (Fig. 1b). AAV-2-specific IgG2 was also
prevalent and detected in more than 95% of samples at a
similar mean concentration (10.8±7.5 mg ml21) (Fig. 1c).
Interestingly, although AAV-2-specific IgG3 was detected
in this donor population, it was uniformly weak (mean
concentration 0.7±0.2 mg ml21) (Fig. 1d) despite strong
IgG3 responses to other unrelated antigens (Supplementary
Fig. S1). Concentrations of the AAV-2-specific IgG4 were
variable (mean 2.5±3.8 mg ml21) (Fig. 1e). Twelve donors
showed no detectable AAV-2-specific IgG4 and only four
of the samples (donors 26, 30, 33 and 49) displayed IgG4
concentrations greater than one standard deviation above
the mean.
AAV-2 induces a recall cell-mediated response
It has been speculated that AAVs do not elicit significant
cell-mediated immune responses (Bu¨ning et al., 2003;
Hernandez et al., 1999; Samulski & Giles, 2005); however,
the detection of a class-switched AAV-2-specific IgG
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response suggested that T-cell help had been evoked by
AAV-2 exposure in the study population. Therefore, the
cell-mediated immune response to AAV-2 was examined.
PBMC were isolated from the same panel of seropositive
donors described above (n541). These cultures were
stimulated in vitro with AAV-2 and assessed for their
capacity to support AAV-2-specific proliferation. PBMC
from 19 of 41 Irish blood donors sampled displayed
significant proliferation in response to restimulation
(Fig. 2). It was therefore clear that AAV-2 induced memory
responses sufficient to support a recall response to
exogenous antigen in a considerable number of donors.
To characterize the cellular response to AAV-2 further,
supernatants from antigen-stimulated cultures (n516)
were assessed for the production of IFN-c, IL-10 and IL-
13, cytokines characteristic of polarized CD4+ T helper cell
recall responses. Ten cultures (donors 13, 15, 27, 31, 32, 38,
40, 41, 50 and 51) produced significantly increased IFN-c
(P¡0.05) (Fig. 3a and Table 1). Cultures from four donors
(27, 31, 32 and 46) showed increased IL-13 (Fig. 3b);
whereas increased IL-10 was present in eight cultures
(donors 31, 38, 40, 43, 45, 47, 50 and 51; mean
concentration 140 pg ml21) (Fig. 3c, Table 1). Although
no clear polarization of cytokine responses was seen in this
population, the detection of IFN-c, IL-10 or IL-13 in recall
responses suggested that long-lived CD4+ T-cell responses
were evoked by AAV-2 in at least some of the study
population.
Antigenic sequences on AAV-2 recognized by T
cells
There has been limited examination of the targets of cell-
mediated immunity to AAV-2 in humans. Therefore the
ability of synthetic peptides corresponding to AAV-2 VP1
capsid peptides to support recall responses from human
PBMCs was examined. PBMCs from the 16 donors
characterized in Fig. 4 (donors 13, 15, 16, 19, 27, 31, 32,
38, 40, 41, 43, 45, 46, 47, 50 and 51) were stimulated with
Fig. 1. Serological response to AAV-2 in Irish blood donors. (a) AAV-2-specific total IgG in human donor plasma (n545).
Specific IgG was determined by indirect AAV-2 antigen ELISA, normalized by comparison with standard positive and negative
samples. The negative cut-off (dashed line) was defined at 2 SD above the concentration of a known seronegative standard. (b–e)
AAV-2-specific IgG subclasses present in IgG-positive samples (n541). IgG1(b), IgG2 (c), IgG3 (d) and IgG4 (e) determined by
AAV-2-specific direct antigen ELISA for triplicate samples and quantified by comparison with known reference sera.
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overlapping 20-mer peptides corresponding to the com-
plete protein sequence of VP1. The sequence for VP1
contains the full sequence of the alternative capsid proteins
VP2 and VP3, thus stimulation of PBMCs with overlapping
peptides from VP1 allowed identification of stimulatory
epitopes across the entire AAV-2 capsid sequence. Cultures
were assessed for proliferation in response to these antigens
(Fig. 4). A stringent definition of an epitope was chosen;
only stimulating pairs of adjacent 20-mer sequences from
more than one donor were considered to represent an
antigenic sequence recognized by T cells, with the 12-mer
consensus sequence overlap assumed to contain the T-cell
epitope. A total of 17 consensus sequences were identified
that were recognized by two or more donors. These 17
common antigenic sequences (Table 2, labelled epitopes A–
Q) were identified across a total of six donors. All of the
sequences identified showed greater than 85% homology
with high-scored HLA class I- and class II-restricted VP1
epitopes predicted by bioinformatics. A further 42 unique
candidate epitopes were identified that were recognized by
single donors only (Supplementary Table S2, available in
JGV Online).
AAV-2 T-cell epitopes on AAV-2 VP1 may be
presented by multiple HLA haplotypes
T-cell recognition of antigens in mammals is MHC
restricted. Humans are an outbred population with highly
polymorphic HLA profiles. In order to establish if the
AAV-2 epitopes identified were associated with particular
haplotypes, the HLA haplotype for each AAV-2 respondent
donor was determined by SSP PCR for the HLA-A, -B, -C,
DRB and DQB loci (Tables 3 and 4). As expected, the
donors characterized displayed considerable haplotype
diversity. No obvious correlations between HLA expression
and epitope recognition were detectable in a population of
this size; however, the key observation from this study was
that donors of different HLA haplotypes (Tables 3 and 4)
recognized at least 16 epitopes, indicating that certain
regions of the AAV-2 capsid are recognized promiscuously
and may be reasonably considered immunodominant.
DISCUSSION
The paucity of data available on immune responses to
AAV-2 raises the possibility that immunity might com-
plicate the use of AAV-2 as a therapeutic vector. In this
study, AAV-2-specific IgG was present in plasma from 41
of 45 donors sampled (.90%). IgG1 and IgG2 were the
Fig. 2. AAV-2-stimulated human PBMC proliferation in vitro. Proliferation (detectable in 19 of 41 cultures) was determined by
titrated thymidine incorporation for triplicate samples and expressed as SI. Responses were only considered positive (*) if they
supported both a mean SI¢1.5 (dashed line) with a significance of P¡0.05 (paired t-test).
Fig. 3. Cytokine responses to AAV-2-stimulated human PBMCs
in vitro. Production of IFN-c (a), IL-13 (b) or IL-10 (c) by PBMC
cultures (n516, proliferation-positive in Fig. 2) stimulated with
AAV-2. Results are expressed as the mean of triplicate determina-
tions.
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predominant AAV-2-specific subclasses present. IgG3
levels were limited and IgG4 was variable and often absent
entirely. Human T-cell proliferation in response to whole
AAV-2 stimulation was demonstrated in nearly half (19 of
41) of PBMC cultures studied. The cytokine profiles
associated with these responses were diverse, but IFN-c and
IL-13 production were detected. Fifty-nine candidate T-cell
epitopes were identified within the VP1 capsid sequence.
Seventeen epitopes were identified on the VP1 protein of
AAV-2 which were recognized by more than one donor; no
significant correlation between stimulating epitope and
respondent donor HLA haplotype was observed, suggesting
that these represent promiscuously recognized immuno-
dominant epitopes. This study, to our knowledge,
represents the most detailed combined examination of
cell-mediated and humoral immunity to AAV-2 in humans
to date. This study demonstrates that both humoral and
cell-mediated memory for AAV-2 is prevalent in the Irish
population, supporting the hypothesis that immunity will
complicate the use of AAV-2 in therapy. Capsid modifica-
tion strategies are unlikely to be a practical solution due to
the variety of epitopes recognized; however, screening for
patient cell-mediated and humoral responses may be an
invaluable tool in bringing effective AAV-2 vectors to
clinical use.
Given the known prevalence of AAV-2 infection in humans
(Chirmule et al., 1999; Erles et al., 1999; Halbert et al.,
Table 1. Cytokine and serological profiles of cultures responding to AAV-2
Donor AAV-2-specific IgG subclass (% total IgG)* PBMC proliferation (SI) Cytokine increase (pg ml”1)D
1 2 3 4 IFN-c IL-10 IL-13
19 39 59 2 0 1.75 2 2 2
46 48 39 3 9 2.08 2 2 189
45 60 30 3 7 2.20 2 209 2
16 48 49 3 0 2.22 2 2 2
27 48 41 3 8 2.27 5 2 1633
31 90 0 1 8 2.31 7 67 1281
32 32 64 3 0 2.33 3 2 962
47 57 21 4 18 2.39 2 225 2
13 37 53 4 5 2.57 85 2 2
43 33 49 2 15 3.29 2 126 2
51 37 62 2 0 5.10 221 138 2
38 43 37 4 16 6.25 39 91 2
50 29 48 2 20 10.91 546 141 2
40 59 25 4 11 14.77 49 132 2
15 44 49 3 3 18.65 110 2 2
41 22 75 1 2 25.50 532 2 2
*AAV-2-specific IgG subclass levels were determined by indirect ELISA. Detectable specific subclass levels are expressed as a percentage of the total
specific IgG.
DCytokine levels in proliferation assay supernatants were determined by sandwich ELISA. Intermediate and negative cytokine production levels are
indicated (2). Increases, where applicable, are measured in pg ml21.
Fig. 4. Human PBMC proliferation in response to peptides corresponding to AAV-2 VP1. PBMCs (representative donor 51
shown here) were cultured in the absence (”, negative control) or presence (+, positive control) of 40 mg peptide or
mitogen ml”1. Peptide sequences (numbered 1–91) are given in Supplementary Table S1. Proliferation of greater than one SD
above the mean was considered positive. Results are expressed as the mean of triplicate determinations.
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Table 2. Common VP1 consensus sequences recognized by human PBMCs
Peptide* VP1 consensus sequenceD Responding donors SYFPEITHI prediction Epitope
Class I scored Class II score§
321–333 KEVTQNDGTTTI 16, 19, 50, 51 24 20 A
241–253 TTSTRTWALPTY 16, 50, 51 21 24 B
681–693 EIEWELQKENSK 13, 50, 51 21 26 C
9–21 DWLEDTLSEGIR 16, 50 21 32 D
57–69 NGLDKGEPVNEA 16, 50 20 27 E
113–125 NLGRAVFQAKKR 50, 51 28 20 F
121–133 AKKRVLEPLGLV 40, 50 29 20 G
249–261 LPTYNNHLYKQI 16, 51 24 24 H
257–269 YKQISSQSGASN 16, 51 – 23 I
265–277 GASNDNHYFGYS 16, 51 26 – J
313–325 FKLFNIQVKEVT 16, 50 – 23 K
329–341 TTTIANNLTSTV 19, 50 22 24 L
393–405 YCLEYFPSQMLR 16, 50 21 28 M
457–469 QSRLQFSQAGAS 13, 16 – 25 N
553–565 DIEKVMITDEEE 13, 50 21 30 O
716–728 TNGVYSEPRPIGTRYLT 16, 51 24 21 P
505–516 ATKYHLNGRDSL 13, 50, 51 21 25 Q
*Peptide number corresponds to amino acid sequence of VP1. The full lists of peptides and sequences are detailed in Supplementary Tables S1
and S2.
DConsensus sequences were derived from the 12-mer overlap between pairs of PBMC-stimulating VP1 peptides with the exception of the overlap
between peptides 90 and 91 which was of 17 amino acids. Pairs of peptide were considered positive if both produced an SI value .1 SD above the
mean SI.
dVP1 sequence was analysed using SYFPEITHI prediction for alleles of the HLA-A and HLA-B loci; output sequences were nonamers. Scores
represent an arbitrary peptide binding capacity for each peptide.
§VP1 sequence was analysed using SYFPEITHI prediction for alleles of the HLA-DRB locus; output sequences were 15-mers. For both class I and II,
the best score obtained is reported. Scores below 20 are not reported.
Table 3. HLA profile of donor PBMCs responding to AAV-2
Donor Class I HLA allele* Class II HLA allele*
13 A2, B7, B13, Cw5, Cw7 DR4/DR53, DR7/DR53, DQ2, DQ8(3)
15 B7, B8, Cw7 DR17(3)/DR52, DR15(2)/DR51, DQ2, DQ6(1)
16 A1, Cw7, Cw7 DR17(3)/DR52, DR51, DQ2, DQ6(1)
19 A68, B8, Cw7, Cw8 DR3/DR52, DR17(3)/DR52, DQ2, DQ6(1)
27 A1, A2, B*4440, B*5615, Cw5, Cw7 DQ2, DQ7(3)
31 A1, B8, B51(5) DR17(3)/DR52, DR8, DQ2, DQ4
32 A1, A29(19), Cw7, Cw7 DR17(3)/DR52, –/DR52, DQ2, DQ6(1)
38 A1, B63(15), B44(12), Cw5, Cw7 DR4/DR53, DR13(6)/DR52, DQ7(3), DQ6(1)
40 Cw1, Cw7 DR1, DR7/DR53, DQ2, DQ5(1)
41 A2, B44(12), B47, Cw4 DR4/DR53, DR7/DR53, DQ2, DQ7(3)
43 A31(19), B7, B71(70), Cw18, Cw6, Cw18 DR4/DR53, DR15(2)/DR51, DQ6(1), DQ6(1)
45 A2, A24(9), B7, B18, Cw5, Cw7 DR17(3)/DR52, DR15(2)/DR51, DQ2, DQ6(1)
46 B55(2), Cw1, Cw4 DR103, DR13(6)/DR52, DQ5(1), DQ6(1)
47 A1, B42 DR4/DR53, DR4/DR53, DQ8(3), DQ5(1)
50 A31(9), B*14, B*14, Cw*06, Cw*08 DR13(6)/DR52, DR15(2)/DR51, DQ9(3)
51 A66(10)/A26(10), B44(12), B57(17), Cw5, Cw6 DR4/DR53, DR15(2)/DR51, DQ6(1), DQ6(1)
*HLA type I and II alleles were determined by SSP PCR. Alleles omitted where not determined.
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2006), it is conceivable that widespread humoral memory
for the virus might negatively affect the usefulness of the
virus as a gene therapy vector. In this study, 41 of 45
donors studied displayed significant titres of AAV-2-
specific IgG in blood plasma (Fig. 1). Although this is
the largest study to examine both humoral and cell-
mediated responses to AAV-2 in the same population, a
sample of 45 donors is still small and larger studies in
populations with greater genetic diversity would be
beneficial. Nevertheless, a seroprevalence greater than
90% is high when compared with AAV-2 seroprevalence
data obtained in other European studies but similar when
compared with populations from the USA (Chirmule et al.,
1999). As no AAV-2-specific IgG standards exist and as
there is no standardized method for assaying AAV-2
antibody, it is likely that the variability observed between
studies is as much a result of differing methods as it is of
geographical differences and population demographics. An
urgent need exists to develop reference standards for AAV
serology; currently it is difficult to compare titres between
studies in a quantitative way.
In this study, AAV-2-specific IgG consisted primarily of
IgG1 and IgG2, with low levels of IgG3 and variable levels
of IgG4 present in all donors (Fig. 1). The presence of IgG1
(Fig. 1b) was expected, as this subclass is commonly
induced following viral infections such as measles, hepatitis
B, human T-lymphotrophic virus type 1 (HTLV-1) and
rubella (Franssila et al., 1996; Gregorek et al., 2000; Lal
et al., 1993; Thomas & Morgan-Capner, 1988; Toptygina
et al., 2005). IgG1 is also induced by B19V which, like
AAV-2, is a member of the parvoviridae (Franssila et al.,
1996). IgG2 was also a major constituent of the AAV-2-
specific antibody response, comprising an average 42% of
total IgG (Fig. 1c). The proportions of AAV-2-specific IgG1
and IgG2 detected in this study broadly agree with data
recently reported by Murphy et al. (2009). Whilst IgG2 is a
component of serological responses to measles and HTLV-
1, it is notable that it is not a significant component of the
response to the parvovirus B19V (Franssila et al., 1996; Lal
et al., 1993; Toptygina et al., 2005). This suggests that there
are differences between how the immune response develops
against B19V and AAV-2, perhaps reflecting the require-
ment of AAV for a helper virus to disseminate.
The IgG3 subclass is usually a significant component of
virus-induced IgG, typically comprising 12–50% of
circulating virus-specific IgG for measles, rubella, HTLV-
1 and hepatitis B in seropositive individuals (Gregorek
et al., 2000; Kalvenes et al., 1996; Lal et al., 1993; Toptygina
et al., 2005). Although AAV-2-specific IgG3 was detected in
all seropositive donors characterized, this subclass con-
stituted an average of just 2.6% (0.7±0.2 mg ml21) of the
total AAV-2-specific IgG detected (Fig. 1d and Table 1).
Given the robust humoral response induced by AAV-2, low
levels of IgG3 are surprising but supported by observation
of similar levels from a recent study from the USA
(Murphy et al., 2009). The average concentration of virus-
specific IgG3 (0.6 mg ml21) observed in that study was
similar to our observations; however, we did not observe
any case where IgG3 represented more than 6% of total
AAV-2-specific IgG from any donor examined (Table 1).
The difference between the results reported by Murphy
et al. (2009) and those reported here may reflect differences
in population genetic background, or the prevalence and
nature of various helper virus infections.
The low seroprevalence of IgG3 against AAV-2 deserves
further attention. Recognition of a particulate antigen in
the inductive immune sites of the upper respiratory tract
typically produces a higher proportion of IgG3-producing
B cells than recognition in the circulatory system (Jefferis &
Kumararatne, 1990). Given that the route of natural AAV-
2 infection is oral/respiratory tract (Blacklow et al., 1968a;
Gould & Favorov, 2003; Rabinowitz & Samulski, 2000), the
failure of AAV-2 to induce significant IgG3 in any donor
examined here is unexpected. It might be that AAV-2 has
some capacity to evade or subvert strong IgG3 induction,
which would represent a means of evading the complement
cascade. This hypothesis is supported by the observation
that the classical complement pathway is only induced
weakly by high titres of AAV-2 and the alternative
complement pathway is not activated (Zaiss et al., 2008).
As IgG3 is the primary IgG subclass involved in the
Table 4. Donor PBMCs with diverse HLA haplotypes recognize common consensus sequences of AAV
ND, Not determined.
Donor HLA class I* HLA class II* Epitopes recognized
A B C DR DQ
13 ND ND Cw1, Cw7 DR1, DR7/DR53 DQ2, DQ5(1) C, N, O, Q
16 A68 B8 Cw7, Cw8 DR3/DR52, DR17(3)/DR52 DQ2, DQ6(1) A, B, D, E, H, I, J, K, M, N, P
19 A2 B7, B13 Cw5, Cw7 DR4/DR53, DR7/DR53 DQ2, DQ8(3) L
40 A1 B42 ND DR4/DR53, DR4/DR53 DQ8(3), DQ5(1) G
50 ND B55(2) Cw1, Cw4 DR103, DR13(6)/DR52 DQ5(1), DQ6(1) A, B, C, D, E, F, G, K, L, M, O, Q
51 A31(19) B7, B71(70) Cw18/Cw6, Cw18 DR4/DR53, DR15(2)/DR51 DQ6(1), DQ6(1) A, B, C, F, H, I, J, P, Q
*HLA class I and II alleles were determined by SSP PCR.
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recruitment of C1, an initiator of the classical complement
pathway, the lack of IgG3 induction observed in this study
may explain results from previous studies (Zaiss et al.,
2008). A weak IgG3 response has also been observed
against B19V, where virus-specific IgG3 levels are high in
early infection but decline significantly over time
(Corcoran et al., 2000; Franssila et al., 1996).
AAV-2-specific IgG4 represented less than 10% of total
IgG and levels were variable (2.5±3.8 mg ml21) (Fig. 1e).
In comparison with the serology of other viruses, variable
IgG4 levels are perhaps unremarkable. Hepatitis B infection
and vaccination typically induce little IgG4, but levels
increase post-infection or vaccination. Variable titres of
IgG4 are also seen in B19V infection, and typically this is
not observed until some 200 days post-infection (Franssila
et al., 1996). IgG4 is a feature of the response to HTLV-1
and measles (Lal et al., 1993; Toptygina et al., 2005). If the
temporal characteristics of AAV-2 serology mirror those of
parvovirus B19V, the minimal IgG3 and elevated IgG4
levels detected here may be representative of late
convalescent AAV-2 infections. As IgG3 and IgG4 levels
are an indicator of the stage of convalescence in B19V
infection (Franssila et al., 1996), further examination of the
temporal characteristics of IgG3 and IgG4 induction in
AAV-2 infection might be useful.
Few studies have examined human cell-mediated immune
responses to AAV-2 (Chirmule et al., 1999; Manno et al.,
2006). This study demonstrated that AAV-2 evokes robust
proliferative and cytokine recall responses detectable from
PBMC cultures. Of the 41 donors examined, 19 demon-
strated a statistically significant proliferative response to
stimulation with AAV-2 (Fig. 2). Chirmule et al. (1999)
also examined human PBMC proliferation in response to
AAV-2 but found that only 3 of 57 of their subjects
produced a stimulation index greater than 2.0. This
discrepancy may be due to the relatively low concentration
of AAV-2 used for the restimulation in that study (m.o.i. of
100, compared with 10 000 here).
The cytokine profiles evoked by AAV-2 did not exhibit
consistent Th1 or Th2 polarization in this study. IFN-c was
the most frequently detected cytokine (Fig. 3a), indicating
that, in some subjects, AAV-2 evokes a Th1-like response.
IL-13, an indicator of Th2 responses, was only detected
from weakly proliferating cultures (SI between 1.5 and 3)
(Fig. 3b) whereas IL-10 production was detected across a
range of donors (Fig. 3c). Chirmule et al. (1999) also
examined AAV-2-stimulated PBMC cultures for cytokines,
finding IFN-c and IL-10 in 6 and 12% of the cultures, but
these authors examined IL-4 instead of IL-13, failing to
find the cytokine in any culture.
The AAV-2 capsid is composed of three proteins: VP1, VP2
and VP3 in a ratio of 1 : 1 : 20 (Xie et al., 2002). VP2 and
VP3 are products of the splicing of VP1 mRNA and both
proteins represent a sub-sequence of the VP1 protein.
Using a conservative definition, 17 epitopes were identified
as recognized on the capsid of AAV-2 VP1 (Table 2). A
further 42 sequences were recognized by a single donor
each (Supplementary Table S2). Limitations in assay
sensitivity and the conservative epitope definition
employed mean that it is likely that more epitopes are
recognized than defined in this study.
The panel of epitopes identified herein includes some
sequences (Supplementary Table S2) previously identified
in human and mouse studies (Chen et al., 2006; Manno
et al., 2006; Sabatino et al., 2005). The RDSLVNPGPAMA
and EIQYTSNYNKSV sequences recognized by donor 13
were similar to sequences identified in C57BL/6 mice
(Sabatino et al., 2005). The sequence GFRPKRLNFKLF
recognized by donor 16 shares an 11 aa identity with a 15-
mer sequence identified in BALB/c mice (Sabatino et al.,
2005). Likewise, the sequence VPQYGYLTL identified as
an epitope in BALB/c mice (Sabatino et al., 2005) as well as
in a single human case by Manno et al. (2006) lies within
the sequence VFMVPQYGYLTL identified as a candidate
epitope for donor 16. Furthermore, Chen et al. (2006)
identified an immunogenic sequence TSADNNNSEYS-
WTGA in mice which spans two sequences recognized by
donor 50 (SKTSADNNNSEY and NSEYSWTGATKY).
The panel of 17 epitopes recognized by two or more donors
in this study have not been previously identified in human
or animal models, with two exceptions. Chen et al. (2006)
identified the sequence QVSVEIEWELQKENS in mice, and
this sequence shares 11 aa with the candidate epitope
EIEWELQKENSK (sequence C, Table 2) recognized by
three donors (13, 50 and 51) in this study. The second
sequence, FKLFNIQV (sequence K, Table 2), was recog-
nized by donors 16 and 50 and is homologous to a
sequence identified in mice by Sabatino et al. (2005).
Sequences B and C were each recognized by three donors,
whilst sequence A was recognized by four. One limitation
of the approach employed to identify these sequences was
the peptide of only 12 residues, a size that would not be
optimal for defining class II-restricted epitopes.
Furthermore, the definition used here to delineate T-cell
epitopes was stringent. Therefore, the present study has
probably underestimated the number of T-cell epitopes for
AAV-2 recognized by the study population. Despite these
limitations, the number of epitopes identified highlights
both the prevalence and diversity of T-cell memory for
AAV-2 in the study population.
It was not possible to identify a correlation between donor
HLA haplotype and the corresponding epitopes recognized
in this study. Now that a large number of epitopes of
AAV-2 have been identified, it would be valuable in future
to use a larger sample size and include approaches to assign
particular epitopes to specific HLA alleles. The haplotypes
of AAV-2 responding donors did display diversity
(Table 3). This was also the case for donors responding
to the most common stimulating capsid sequences
(Table 4). It is reported here that the DQ2, DQ3
[DQ7(3), DQ8(3), DQ9(3)] and DQ6(1) serotype alleles
were present at high frequencies in our study group. These
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results agree with recent detailed examinations of HLA
allele frequencies and haplotypes in the Irish population
(Dunne et al., 2008). The observation that a number of
AAV-2 sequences can be recognized by donors with
different HLA haplotypes, and indeed across species,
indicates that the epitopes described in Table 2 might
reasonably be considered to be immunodominant human
T-cell epitopes.
It is intriguing that recent reports have indicated successful
therapeutic use of AAV via the subretinal route (Hauswirth
et al., 2008) whilst intravenous and intramuscular admin-
istrations have been less successful (Brantly et al., 2006;
Manno et al., 2006). The prevalence of humoral and cell-
mediated immunological memory for AAV-2 demon-
strated here is likely to contribute to the failure of
intravenous and intramuscular administration. Such lim-
itations might not apply to antigen encountered via the
eye; it is well known that powerful immunosuppressive
effects can be induced when antigen is introduced to the
ocular anterior chamber leading to the phenomenon of
anterior-chamber-associated immune deviation (Streilein,
2003). It may be that a subretinal route for AAV gene
therapies induce such phenomena and avoid confounding
immunological memory.
It has been suggested that AAV-2 capsid modification
enhances the efficacy of the virus as a vector (Monahan &
Samulski, 2000) or that immunosuppressive drugs follow-
ing vector administration prevent cell-mediated immunity
(Manno et al., 2006). However, systemic immunosuppres-
sion may be undesirable in candidates for gene therapy and
thus the immunodominant sequences identified here may
thus represent appropriate targets for capsid modification
in rare cases. Nevertheless, our observation that even a
small sample of an outbred population can support diverse
recall response against multiple T-cell epitopes means that
genetic modification of AAV-2 to escape immune recog-
nition by T cells fully is not a feasible goal. Vector capsid
modification to remove identified epitopes might instead
represent a strategy reserved for specific cases in which
administration of immunosuppressive drugs is undesirable.
Serology did not reliably predict the quality of T-cell
memory for AAV-2 (Table 1). Thus, detailed combined
screening of patient antibody and T-cell epitope recog-
nition would be valuable tools in such cases.
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